Gastroparesis
Gastroparesis Registry
IRB number: HUM00009103
The purpose of the national Gastroparesis Registry is to better understand gastroparesis by following and periodically evaluating people with this condition. The data collected through this research study will improve the diagnosis and treatment of patients with gastroparesis. The Gastroparesis Registry is an observational study. Treatment for gastroparesis will not be provided by this study. This study is a nationwide study funded by the National Institutes of Health. Participation could last up to 4 years.
Main Inclusion Criteria
- Must have delayed gastric emptying and/or symptoms of gastroparesis within the last 6 months.
- Must have had an upper endoscopy within the past 12 months.
- Nausea, vomiting, early satiety (a sense that you cannot finish a normal-sized meal), fullness after eating, and abdominal pain associated with gastroparesis.
Age: 18 years and older
Gender: Male and female
Ethnicity: All
Race: All
Smoking: Smoking and nonsmoking volunteers
Medication: No restriction
Study population: patients with symptoms of gastroparesis
Other eligibility factors
Location of Study Visits
- Ann Arbor
Prinicipal Investigator:
- William L Hasler, MD
Contact:
- Michelle Atkinson 734-615-6723 or e-mail: michcast@umich.edu
This clinical study is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). For more information provided by NIDDK, click on the following link: Nortriptyline for Idiopathic Gastroparesis
Nortriptyline for idiopathic gastroparesis: a multicenter, randomized, double-masked, placebo-controlled trial
IRB number: HUM00021678
The purpose of this study is to find out whether treatment with the medication nortriptyline is better than a placebo in improving the symptoms of gastroparesis – specifically, the type of gastroparesis called "idiopathic," which means "of unknown cause or origin." Nortriptyline is approved by the United States Food and Drug Administration for treatment of depression. It is not currently approved for treating symptoms of gastroparesis.
Eligibility
Age Range: From 25 to 65 years
Gender: Male & female
Ethnicity: All
Race: All
Smoking: Both smoking and non-smoking volunteers
Medication: Not taking medication
Study population: patients with symptoms of gastroparesis
Other Eligibility Factors
- Documentation of delayed gastric emptying within 2 years.
- Negative upper endoscopy or upper GI series within 2 years of registration date.
- Symptoms of gastroparesis for at least 6 months (does not have to be contiguous)
Prinicipal Investigator:
- William L Hasler, MD
Contact:
- Michelle Atkinson 734-615-6723 or e-mail: michcast@umich.edu
This clinical study is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). For more information provided by NIDDK, click on the following link: Gastroparesis Registry
